Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.8489
-0.0411 (-4.62%)
Dec 16, 2025, 2:47 PM EST - Market open
Lexaria Bioscience Employees
Lexaria Bioscience had 7 employees as of August 31, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$100,846
Profits / Employee
-$1,700,263
Market Cap
18.87M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 7 | 0 | - |
| Aug 31, 2024 | 7 | 2 | 40.00% |
| Aug 31, 2023 | 5 | -2 | -28.57% |
| Aug 31, 2022 | 7 | 1 | 16.67% |
| Aug 31, 2021 | 6 | 2 | 50.00% |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LEXX News
- 1 day ago - Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 4 weeks ago - Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended - Accesswire
- 2 months ago - Lexaria Bioscience Corp. Provides Strategic Update - Accesswire
- 2 months ago - Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 2 months ago - Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - TheNewswire
- 3 months ago - Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain - Accesswire
- 3 months ago - Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference - TheNewswire
- 4 months ago - Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone - Accesswire